Following consent, 20 patients will undergo quality of life (QOL) and neurocognitive baseline testing, followed by LITT using the NBS and intra-operative magnetic resonance imaging (MRI). Within 7 days of LITT, patients will initiate SCRT. Dose for radiation therapy (RT) will be prescribed to the maximum isodose line completely encompassing the target volume using the guidelines established in Radiation Therapy Oncology Group (RTOG) 0320. Fractionated therapy (i.e. 5 Gray/fraction x 5 daily fractions) is permitted as dictated by safety guidelines for a given lesion. Following SCRT, patients may be treated with adjuvant (preferably 50 mg /m2/daily) temozolomide (TMZ) cycles up to 12 months at the discretion of the treating oncologist based on standardized eligibility criteria. QOL and neurocognitive testing will be repeated at SOC clinic visits 1, 3, 6, 12, and 24 months following LITT operation. The study population includes newly diagnosed GBM patients who are unable to undergo broader surgical resection.